Paclitaxel exposure-toxicity analysis reveals a pharmacokinetic determinant for dose-limiting neutropenia in East-Asian solid tumor patients: results from two prospective, phase II studies-Reference-Cited by-同舟云学术

Paclitaxel exposure-toxicity analysis reveals a pharmacokinetic determinant for dose-limiting neutropenia in East-Asian solid tumor patients: results from two prospective, phase II studies

Published:2022-08-03 Issue:3 Volume:90 Page:229-237
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Xue Jinhui,He Haipeng,Lin Zuan,Wu Yuehan,Lin Yuehao,Zhao Hongyun,Salamone Salvatore J.,Huang Yan,Yang Yunpeng,Fang Wenfeng,Zhang Yang,Hong Shaodong,Ma Yuxiang,Zhang Li^ORCID

Funder

National Natural Science Foundation of China

Guangdong Basic and Applied Basic Research Foundation

Bristol-Myers Squibb

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-022-04456-w.pdf

Reference45 articles.

1. Kumar N (1981) Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 256(20):10435–10441

2. Weaver BA (2014) How Taxol/paclitaxel kills cancer cells. Mol Biol Cell 25(18):2677–2681. https://doi.org/10.1091/mbc.E14-04-0916

3. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676. https://doi.org/10.1056/NEJMoa072113

4. Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr (2005) Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23(25):5883–5891. https://doi.org/10.1200/jco.2005.55.405

5. Fountzilas G, Papakostas P, Dafni U, Makatsoris T, Karina M, Kalogera-Fountzila A, Maniadakis N, Aravantinos G, Syrigos K, Bamias A, Christodoulou C, Economopoulos T, Kalofonos H, Nikolaou A, Angouridakis N, Stathopoulos G, Bafaloukos D, Pavlidis N, Daniilidis J (2006) Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 17(10):1560–1567. https://doi.org/10.1093/annonc/mdl151